Smith-Moore to speak at NIH/FDA-sponsored workshop on expanding AAV manufacturing capacity

Published January 27, 2020

Dr. Caroline Smith-Moore, assistant director for BTEC's analytical lab, will serve as a panelist during a Jan. 28–29 workshop on expanding AAV manufacturing capacity for rare disease gene therapies. The event is co-hosted by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) and the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) The event will take place on the NIH campus in Bethesda, Md. Smith-Moore will participate in a Jan. 28 session on major logistical bottlenecks and discuss the necessity of developing a pipeline of skilled talent for gene therapy manufacturing.

Current adeno-associated virus (AAV) manufacturing capacity cannot keep pace with the demand for AAV gene therapy clinical trials. The meeting will bring together thought leaders, key stakeholders and innovators to explore obstacles and identify opportunities for expanding the capacity of AAV manufacturing for rare disease gene therapies.

The workshop is presented without charge. Those unable to attend in person may view a live videocast of the program. A recording of the workshop will also be available after the event. For more information, visit the program website.